Cipla's Pune Godown Loses Drug Licence Over 'Misbranding, Storage Violations'
Direct Source Verification:
This story is aggregated from NDTV (ndtv.com). Full reporting rights and copyright belong to the primary publisher.
A major reason for the action was the misbranding of 'Reactin Plus', a Schedule-H drug that cannot be sold over the counter.
For complete coverage, context, and related multimedia, visit the original reporting by NDTV via the source link below.
Original Source
https://www.ndtv.com/india-news/ciplas-pune-godown-loses-drug-licence-over-misbranding-storage-violations-12131164#publisher=newsstand
